Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Centessa Pharmaceuticals Limited Market Cap
Based on ratings from 0 stock analysts, the Centessa Pharmaceuticals Limited stock price is expected to increase by 66.92% in 12 months. This is calculated by using the average 12-month stock price forecast for Centessa Pharmaceuticals Limited. The lowest target is $19 and the highest is $35. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assigned CNTA 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Centessa Pharmaceuticals Limited to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on CNTA. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of CNTA.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Jeffrey Hung Morgan Stanley | Overweight | $26 | Upgrade | Sep 19, 2024 |
| Mayank Mamtani B. Riley Securities | Buy | $33 | Initiates | Sep 19, 2024 |
| Kostas Biliouris BMO Capital | Outperform | $35 | Maintains | Sep 16, 2024 |
| Kelly Shi Jefferies | Buy | $19 | Maintains | Sep 11, 2024 |
| Debjit Chattopadhyay Guggenheim | Buy | $24 | Maintains | Sep 11, 2024 |
| Kostas Biliouris BMO Capital | Outperform | $20 | Maintains | Sep 9, 2024 |
| Francois Brisebois Oppenheimer | Outperform | $14 | Reiterates | Aug 14, 2024 |
| Francois Brisebois Oppenheimer | Outperform | $14 | Initiates | Jul 18, 2024 |
| Matthew Harrison Morgan Stanley | Equal-Weight | $11 | Maintains | Jun 21, 2024 |
| Kostas Biliouris BMO Capital | Outperform | $15 | Maintains | Apr 1, 2024 |
| Kelly Shi Jefferies | Buy | $11 | Upgrade | Nov 15, 2023 |
| Matthew Harrison Morgan Stanley | Equal-Weight | $8 | Upgrade | Oct 26, 2023 |
| Debjit Chattopadhyay Guggenheim | Buy | $10 | Maintains | Aug 15, 2023 |
| David Risinger SVB Securities | Outperform | $11 | Maintains | Aug 15, 2023 |
| Salveen Richter Goldman Sachs | Neutral | $5 | Maintains | Aug 15, 2023 |
| Kostas Biliouris BMO Capital | Outperform | $15 | Maintains | Jul 25, 2023 |
| Umer Raffat Evercore ISI Group | Outperform | Initiates | Jun 21, 2023 | |
Guggenheim | Buy | Initiates | Jun 12, 2023 | |
| Salveen Richter Goldman Sachs | Neutral | $4.5 | Maintains | May 15, 2023 |
| David Risinger SVB Leerink | Outperform | $6 | Initiates | Mar 17, 2023 |
When did it IPO
2021
Staff Count
72
Country
United Kingdom
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Saurabh Saha M.D., Ph.D.
Market Cap
$2.00B
In 2023, CNTA generated $6.9M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that CNTA's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Sat, 28 Sep 2024
Sentiment - POSITIVE
Source - MarketBeat
Summary - Centessa Pharmaceuticals (NASDAQ: CNTA) has nearly doubled in value this year, with Morgan Stanley significantly raising its price target, indicating potential for further growth.
Why It Matters - Centessa Pharmaceuticals' stock surge and raised price target from Morgan Stanley signal strong growth potential, attracting investor interest and possibly leading to further price appreciation.
Thu, 26 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - ORX142 shows promise as a novel treatment for excessive daytime sleepiness in certain neurological, neurodegenerative, and psychiatric disorders, based on recent non-human primate data.
Why It Matters - Positive NHP data for ORX142 suggests potential market entry in treating EDS, indicating growth opportunities and possible revenue streams in neurology and psychiatry sectors.
Tue, 10 Sep 2024
Sentiment - POSITIVE
Source - Investors Business Daily
Summary - Centessa's stock rose following positive test results for a potential blockbuster narcolepsy treatment, according to an analyst.
Why It Matters - Positive test results for Centessa's narcolepsy treatment can lead to increased revenues, market share, and investor confidence, driving stock prices higher.
Tue, 10 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Centessa Pharmaceuticals reported positive interim results for its OX2R agonist, ORX750, showing significant improvements in sleep latency and a favorable safety profile. Plans for Phase 2 trials in 2024 are underway.
Why It Matters - Positive interim trial results for Centessa's ORX750 could indicate strong market potential, leading to increased investor confidence and potential price appreciation for CNTA shares.
Wed, 11 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Centessa Pharmaceuticals (Nasdaq: CNTA) announced a $150 million public offering of American Depositary Shares, with a 30-day option for underwriters to purchase an additional $22.5 million.
Why It Matters - Centessa Pharmaceuticals' $150 million public offering may dilute existing shares but can provide critical funding for research, impacting future growth and stock valuation.
Thu, 12 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Centessa Pharmaceuticals priced a public offering of 15,254,237 ADSs at $14.75 each, aiming for $225 million in gross proceeds. The offering closes around September 16, 2024.
Why It Matters - Centessa Pharmaceuticals' $225 million capital raise indicates strong investor interest and enhances its funding for drug development, potentially impacting future growth and stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
